Document is current

Article History

Received: 13 June 2023

Accepted: 29 September 2023

First Online: 19 October 2023

Declarations

:

: Ethical approval to conduct this survey was obtained from Newcastle University Faculty of Medical Sciences Ethics Committee in February 2023 (application number 2453/26903/2021). In-country ethics approvals are either in place or in process at the time of publication. All methods will be carried out in accordance with relevant guidelines and regulations. Informed consent will be obtained from all subjects prior to their participation in any study aspect.

: Not applicable.

: Roberto Cilia has received speaking honoraria from Zambon Italia; Zambon SAU; Bial Italia Srl; Advisory board fees from Bial; Research support from the Italian Ministry of Health (Principal Investigator of the project GR-2018–12366771 and Co- Principal Investigator of the project PNRR-MR1-2022–12376921); Editor-in-chief of the neuromuscular and movement disorders section of Brain Sciences; Associate Editor of Parkinsonism and Related Disorders, Frontiers in Neuroscience section Neurodegeneration and Frontiers in Aging Neuroscience.Silvia Del Din reports consultancy activity with Hoffmann-La Roche Ltd. outside of this study. SDD was also supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). SDD was also supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) project IDEA-FAST—Grant Agreement 853981. SDD was supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) based at The Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle University and the Cumbria, Northumberland and Tyne and Wear (CNTW) NHS Foundation Trust. SDD and LR were supported by the NIHR/Wellcome Trust Clinical Research Facility (CRF) infrastructure at Newcastle upon Tyne Hospitals NHS Foundation Trust.Oluwadamilola Ojo receives Honoraria from the International Parkinson and Movement Disorder Society (MDS) for educational courses on Movement Disorders as Faculty and support for attending meetings and/or travel, and funding for a leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid—Member, Executive Committee, MDS African Section.Njideka Okubadejo receives research grants from the Michael J Fox Foundation for Parkinson's Research (Parkinson Progression Markers Initiative and PD Genetic Diversity in Africa) and Honorarium from the International Parkinson and Movement Disorder Society (IPMDS).Lynn Rochester is a member of Endpoints Advisory Group—MJ Fox Foundation and receives consultancy for the role.All other authors declare that they have no competing interests.